Klus Pharma
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Klus Pharma sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Klus Pharma: 3 sponsored US clinical trials, none currently recruiting.
Klus Pharma sponsors 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Endometrial Carcinoma, with 1 trials.
Upper-quartile sponsor footprint
Klus Pharma sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
3 total, page 1 of 1
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
NCT05642780
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
NCT04152499
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
NCT03602079
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
How the Klus Pharma early-phase archive is shaped
3 indexed studies, none listed as recruiting (0% open); 1 completed (33%).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Endometrial Carcinoma (1 trial), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Klus Pharma: archived-pipeline peers nationwide
Peers matched on 3 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Klus Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 archived trials
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
- 3EO Health · 0% recruiting · 2 trials
Related
What to do with this Klus Pharma page
3 registered trials is a research-attention snapshot, not an endorsement of Klus Pharma or any single study.
- None of Klus Pharma's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Endometrial Carcinoma is the condition Klus Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Endometrial Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Klus Pharma pipeline card: 3 registered trials from official public datasets.Report a data error.